|
Drug-induced tardive dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although met with conflicting data, the following genes may be involved with TD development: the cytochrome P450 gene CYP2D6, involved with metabolism of most antipsychotics, Dopamine D2 and D3 receptor genes, serotonin 2A and 2C receptor genes, vesicular monoamine transporter 2 (VMAT 2) gene, involved with intracellular neurotransmitter packaging, and the manganese superoxide dismutase (MnSOD) gene, an antioxidant enzyme.
|
30522959 |
2019 |
|
Drug-induced tardive dyskinesia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This is the first study to examine the association between TD and CYP2D6 in Caucasians with this number of genotypic categories.
|
24595968 |
2014 |
|
Drug-induced tardive dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Numerous studies have shown a significant association between genotype and adverse effects, such as CYP2D6 polymorphisms and tardive dyskinesia.
|
23870808 |
2013 |
|
Drug-induced tardive dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In patients tested for CYP2D6, an association between genotype and tardive dyskinesia (including Abnormal Involuntary Movement Scale scores) was found.
|
20031087 |
2010 |
|
Drug-induced tardive dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
An association between TD and the CYP2D6 100T and CYP1A2 163C alleles was observed.
|
16490169 |
2006 |
|
Drug-induced tardive dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study tested the association between tardive dyskinesia (TD) and polymorphic variations in (a) 2 cytochrome P450 (CYP) genes (CYP2D6 or CYP3A5), (b) 2 DRD2 variants (Ser311Cys and -141C Ins/del) and the Ser9Gly DRD3 variants, (c) 2 glutathione S-transferases (GSTT1 and GSTM1), and (d) variations in the PgP gene, MDR1.
|
16160620 |
2005 |
|
Drug-induced tardive dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms.
|
15820320 |
2005 |
|
Drug-induced tardive dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis.
|
15861039 |
2005 |
|
Drug-induced tardive dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We concluded that the CYP2D6*10 C188T polymorphism may be associated with the susceptibility to the occurrence of TD induced by typical antipsychotics, especially in male patients, and may also be correlated with AIMS scores in TD patients.
|
15118351 |
2004 |
|
Drug-induced tardive dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, no significant difference was observed in the distribution of both CYP2D6*2 (C2938T) and CYP2D6*10 (C188T) polymorphisms between schizophrenic patients with or without tardive dyskinesia.
|
12960748 |
2003 |
|
Drug-induced tardive dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the present case-control study, we tested the putative influence of the CYP2D6 genotype on the development of TD.
|
12734765 |
2003 |
|
Drug-induced tardive dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6.
|
12432967 |
2002 |
|
Drug-induced tardive dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The tendencies for patients carrying at least one mutated CYP2D6 gene to have an increased risk of parkinsonism and TD are in accordance with previous studies.
|
12107620 |
2002 |
|
Drug-induced tardive dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The goal of this study was to determine whether the occurrence of TD is associated with CYP2D6 genotype in a cohort of Korean schizophrenics by employing a CYP450 GeneChip((R)) oligonucleotide microarray and PCR assays to screen for 19 CYP2D6 alleles.
|
12629505 |
2002 |
|
Drug-induced tardive dyskinesia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients.
|
11778144 |
2001 |
|
Drug-induced tardive dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There was a significant difference in the allelic distribution of CYP2D6*10 between subjects with and without TD.
|
9713906 |
1998 |
|
Drug-induced tardive dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
As slight differences in the metabolism of drugs in patients heterozygous for CYP2D6 mutations and patients without such mutations are known, we conclude that heterozygous carriers of 2D6 mutated alleles may show an increased susceptibility to developing TD.
|
9713905 |
1998 |
|
Drug-induced tardive dyskinesia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that genetically impaired CYP2D6 metabolism may be a contributing factor for the development of persistent TD.
|
9201806 |
1997 |
|
Drug-induced tardive dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2D6 genotype is not a determinant of susceptibility to acute dystonic reactions but may be a contributory factor in antipsychotic drug-induced movement disorders including tardive dyskinesia.
|
9068770 |
1997 |
|
Drug-induced tardive dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sixteen white schizophrenic patients who had developed tardive dyskinesia during long-term neuroleptic treatment were phenotyped with debrisoquine and genotyped by CYP2D6-specific DNA amplification and EcoRI restriction fragment length polymorphism analysis.
|
7635999 |
1995 |